In the latest trading session, 0.42 million Lyell Immunopharma Inc (NASDAQ:LYEL) shares changed hands as the company’s beta touched -0.39. With the company’s most recent per share price at $0.71 changing hands around $0.01 or 0.97% at last look, the market valuation stands at $206.71M. LYEL’s current price is a discount, trading about -359.15% off its 52-week high of $3.26. The share price had its 52-week low at $0.51, which suggests the last value was 28.17% up since then.
Analysts gave the Lyell Immunopharma Inc (LYEL) stock a consensus recommendation rating of Hold, calculated at a mean rating of 3.33. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended LYEL as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. Lyell Immunopharma Inc’s EPS for the current quarter is expected to be -0.13.
Lyell Immunopharma Inc (NASDAQ:LYEL) trade information
Instantly LYEL is in green as seen in intraday trades today. With action 15.96%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 10.55%, with the 5-day performance at 15.96% in the green. However, in the 30-day time frame, Lyell Immunopharma Inc (NASDAQ:LYEL) is 21.11% up.
The consensus price target for the stock as assigned by Wall Street analysts is 1, meaning bulls need an upside of 29.0% from its recent market value. According to analyst projections, LYEL’s forecast low is 1 with 1 as the target high. To hit the forecast high, the stock’s price needs a -40.85% plunge from its current level, while the stock would need to soar -40.85% for it to hit the projected low.
Lyell Immunopharma Inc (LYEL) estimates and forecasts
Year-over-year growth is forecast to reach -59.23% down from the last financial year.
The company’s revenue for the corresponding quarters a year ago was 13k. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -100.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -15.28%. The 2025 estimates are for Lyell Immunopharma Inc earnings to increase by 21.51%, but the outlook for the next 5-year period is at 17.62% per year.
Lyell Immunopharma Inc (NASDAQ:LYEL)’s Major holders
ORLAND PROPERTIES LTD holds the second largest percentage of outstanding shares, with 5.91% or 15.09 million shares worth $21.89 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Price (T.Rowe) Health Sciences Fund. With 5.82 shares estimated at $4.11 million under it, the former controlled 1.99% of total outstanding shares. On the other hand, Price (T.Rowe) Health Sciences Fund held about 1.85% of the shares, roughly 5.4 shares worth around $3.82 million.
